GermanyGermany

Germany launches EUR200 million biotechnology research programme

12.07.2010

Berlin – Germany is to invest EUR200 million over the coming 15 years to develop the next generation of biotechnology processes. “The full potential of biotechnology isn’t yet fully exploited”, said BMBF State Secretary Helge Braun during the presentation of the new Biotechnology 2020 Plus programme in Berlin. “We can change this by applying engineering principles to biotechnology.” A long-term goal of the ambitious programme is to separate biological functions from cells, and to create robust reaction modules that can mimic biological processes even under harsh reaction conditions. This would enable engineers to integrate the water-soluble biological processes into existing industrial value chains, for example using cell-free photosynthesis modules for energy production, or artificial enzymes or cell modules to produce chemicals in a solvent-free environment. Because most of these goals are currently more vision than reality, the Ministry for Research has kicked off a so-called strategy process that brings together experts from a variety of fields to discuss the kinds of projects required to realise the biologisation of industrial processes. Four major research organisations have signed a memorandum of understanding to contribute to the process. Synthetic biology is expected to play an important role in the programme.

GermanyGermany

16.07.2010

Hamburg/Göttingen - Hamburg-based drug screening specialist Evotec AG has entered into a definitive agreement with a group of shareholders from diabetes and obesity drug-developer DeveloGen AG to acquire a majority shareholding...

GermanyGermany

11.07.2010

Personalised medicine is all about treating an individual based on the specifics of his or her disease. However, both current EMA or FDA regulations and present clinical practice are stochastic, and thereby fundamentally in...

GermanyGermany

11.07.2010

Leuna – Peak oil prices and depleted fossil resources have dragged biomass into the limelight in the chemical industry. In Germany, pioneering work to use wood waste to produce bioplastics, platform chemicals or energy in a...

GermanyGermany

10.07.2010

Heidelberg – Practically overnight, a deal with Life Technologies has made the German Cancer Research Center (DKFZ) in Heidelberg one of Europe’s largest centres for next-generation sequencing. At the end of June, the researchers...

GermanyGermany

09.07.2010

Göttingen – A drug that regulates release of kidney hormones may help against the symptoms of jet-lag or shift work. In mid-June, Dr. Silke Kiessling and colleagues from the Max Planck Institute for Biophysical Chemistry in...

GermanyGermany

08.07.2010

Hamburg – To survive in man, the malaria parasite Plasmodium falciparum needs to enter the red blood cells for reproduction. Researchers from the Bernhard ­Nocht Institute for Tropical Medicine in Hamburg have now identified the...

GermanyGermany

08.07.2010

Limburgerhof/ St. Louis - To improve crop yield, US and European agrobiotech giants Monsanto and BASF will expand their development and commercialisation alliance aimed at developing higher- yielding and stress-tolerant crops. In...

GermanyGermany

05.07.2010

Martinsried – German antibody specialist MorphoSys AG has signed a worldwide exclusive licensing and collaboration agreement for the humanised Anti-CD19 monoclonal antibody XmAb5574 from US-based Xencor Inc as a potential...

GermanyGermany

02.07.2010

Frankfurt/Stanford – Most types of deafness arise from loss of parts the 15,000 hair cells of the inner ear. A US-German research team headed by Prof. Stefan Heller has, for the first time, succeeded in regenerating hair...

Displaying results 91 to 100 out of 454

< Previous 91-100 Next >

© 2007-2015 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-germany/browse/9/article/germany-launches-eur200-million-biotechnology-research-programme.html

Video

All videos

Product of the week

Products

WhitePaper

LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Events

All Events

Partner-Events

München

BioVaria 2015

Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...

Stock list

All quotes

TOP

  • WILEX3.59 EUR5.59%
  • BASILEA118.10 CHF3.14%
  • PAION2.58 EUR2.79%

FLOP

  • BIOTEST79.20 EUR-19.51%
  • CYTOS1.01 CHF-8.18%
  • FORMYCON28.00 EUR-6.01%

TOP

  • 4SC1.30 EUR54.8%
  • WILEX3.59 EUR22.9%
  • CO.DON3.15 EUR19.3%

FLOP

  • MOLOGEN5.08 EUR-35.6%
  • CYTOS1.01 CHF-34.4%
  • BIOTEST79.20 EUR-22.5%

TOP

  • SANTHERA98.85 CHF2460.9%
  • CYTOS1.01 CHF676.9%
  • WILEX3.59 EUR337.8%

FLOP

  • MOLOGEN5.08 EUR-54.7%
  • THERAMETRICS0.07 CHF-30.0%
  • BIOFRONTERA2.41 EUR-28.1%

No liability assumed, Date: 24.04.2015

Current issue

All issues